Evidence map›Paper›PMID 24469092›Full record

ArticleProstate cancer and prostatic diseases2014

ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer.

J R Gsponer, M Braun, V J Scheble, T Zellweger, A Bachmann, S Perner, T Vlajnic, M Srivastava, S H Tan, A Dobi and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. BMJ open · 2019
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

J R GsponerInstitute for Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
M BraunDepartment of Prostate Cancer Research, Institute of Pathology, University Hospital of Bonn, Bonn, Germany.
V J SchebleInstitute of Pathology, Comprehensive Cancer Center, University Hospital Tuebingen, Tuebingen, Germany.
T ZellwegerDivision of Urology, St Claraspital, Basel, Switzerland.
A BachmannDepartment of Urology, University Hospital Basel, University of Basel, Basel, Switzerland.
S PernerDepartment of Prostate Cancer Research, Institute of Pathology, University Hospital of Bonn, Bonn, Germany.
T VlajnicInstitute for Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
M SrivastavaDepartment of Anatomy, Physiology, and Genetics, and Institute for Molecular Medicine, Uniformed Services University of the Health Sciences, School of Medicine, Bethesda, MD, USA.
S H TanCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
A DobiCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
I A SesterhennJoint Pathology Center, Silver Spring, MD, USA.
S SrivastavaCenter for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
L BubendorfInstitute for Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
C RuizInstitute for Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
Uniformed Services University of the Health Sciences · USUniversity of Basel · CHSt. Claraspital · CHUniversity Hospital of Basel · CH

Funding

Cell Specific Expression Signatures in Prostate Cancer (RO1 DK065977)R01CA162383 · NCI · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI SRIVASTAVA, SHIV · 2011 to 2015
$1.1M
Cell Specific Expression Signatures in Prostate CancerR01DK065977 · NIDDK · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI SRIVASTAVA, SHIV · 2004 to 2007
$688k
NCI NIH HHS R01 CA162383NIDDK NIH HHS R01 DK065977
6 · The paper itself

Abstract

backgroundApproximately half of the prostate carcinomas are characterized by a chromosomal rearrangement fusing the androgen-regulated gene TMPRSS2 to the oncogenic ETS transcription factor ERG. Aim of this study was to comprehensively analyze the role and impact of the ERG rearrangement and protein expression on the progression to castration-resistant (CR) disease.

methodsWe used a tissue microarray (TMA) constructed from 114 hormone naive (HN) and 117 CR PCs. We analyzed the ERG rearrangement status by fluorescence in situ hybridization and the expression profiles of ERG, androgen receptor (AR) and the proliferation marker Ki67 by immunohistochemistry.

resultsNearly half of the PC tissue specimens (HN: 38%, CR: 46%) harbored a TMPRSS2-ERG gene fusion. HN PCs with positive translocation status showed increased tumor cell proliferation (P<0.05). As expected, TMPRSS2-ERG gene fusion was strongly associated with increased ERG protein expression in HN and CR PCs (both P<0.0001). Remarkably, the study revealed a subgroup (26%) of CR PCs with ERG rearrangement but without any detectable ERG protein expression. This subgroup showed significantly lower levels of AR protein expression and androgen-regulated serum PSA (both P<0.05).

conclusionsIn this study, we identified a subgroup of ERG-rearranged CR PCs without detectable ERG protein expression. Our results suggest that this subgroup could represent CR PCs with a dispensed AR pathway. These tumors might represent a thus far unrecognized subset of patients with AR-independent CR PC who may not benefit from conventional therapy directed against the AR pathway.

Indexed as

Disease ProgressionGene RearrangementHumansKi-67 AntigenMaleOncogene Proteins, FusionProstatic Neoplasms, Castration-ResistantReceptors, AndrogenSerine EndopeptidasesTrans-ActivatorsTranscriptional Regulator ERGTranscriptomeTranslocation, GeneticAR protein, humanERG protein, humanKi-67 AntigenOncogene Proteins, FusionReceptors, AndrogenSerine EndopeptidasesTMPRSS2 protein, humanTrans-ActivatorsTranscriptional Regulator ERG

Identifiers

PMID24469092
PMCPMC4097053
OpenAlexW1988716761

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.